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We examined the impact of pretreatment neutrophil count on survival in patients 
with advanced non-small-cell lung cancer (NSCLC). A total of 388 chemo-naïve 
patients with stage IIIB or IV NSCLC from a randomized controlled trial were 
evaluated. The effects of pretreatment peripheral blood neutrophil, lymphocyte 
and monocyte counts and neutrophil-lymphocyte ratio on survival were 
examined using the proportional hazards regression model to estimate hazard 
ratios after adjustment for covariates. The optimal cut-off value was determined 
by proportional hazards regression analysis with the minimum P-value 
approach and shrinkage procedure. After adjustment for prognostic factors, the 
pretreatment elevated neutrophil count was statistically significantly associated 
with short overall (P=0.0008) and progression-free survival (P=0.024), whereas 
no association was found between prognosis and lymphocyte or monocyte 
count. The cut-off value selected for neutrophil count was 4500/mm3 (corrected 
hazard ratio: 1.67, 95% confidence interval (CI), 1.09-2.54). The median 
survival time was 19.3 months (95%CI, 16.5-21.4) for the low-neutrophil group 
(<4500/mm3, n=204) and 10.2 months (95%CI, 8.0-12.3) for the high-neutrophil 
group (>4500/mm3, n=184). We confirmed that pretreatment elevated neutrophil 
count is an independent prognostic factor in patients with advanced NSCLC 
receiving modern chemotherapy. Neutrophil count is easily measured at low 
 
 
cost, and it may be a useful indicator of patient prognosis. 
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1. Introduction 
The prognosis for patients with advanced non-small-cell lung cancer (NSCLC) 
(TNM stage IIIB with a positive pleural effusion, or stage IV) has improved with 
recent advances in systemic chemotherapy, but still remains poor, with a 
median overall survival time between 4 and 15 months.1 Prognostic factors 
identified in previous studies include tumour stage, performance status (PS), 
weight loss, sex, plasma lactate dehydrogenase (LDH) level and the presence 
of bone, liver or skin metastases.2 Although novel immunological and 
histological biomarkers have been identified, these are often time-consuming to 
measure, and this is not part of standard practice. 
It is now evident that inflammatory cells in the tumour microenvironment 
have significant effects on tumour development.3-6 Elevation in the pretreatment 
neutrophil count has been proposed as a prognostic factor for poor survival in 
patients with metastatic renal cell carcinoma,7-9 and elevated neutrophil, 
monocyte or leukocyte count has been associated with poor survival in patients 
with metastatic melanoma.10,11 A high neutrophil-lymphocyte ratio may be 
related to poor prognosis in patients with colorectal cancer12 and in those with 
advanced gastric cancer.13 The European Lung Cancer Working Group found 
that the high-neutrophil count was an independent prognostic factor for poor 
survival in patients with unresectable advanced NSCLC14 and in those with 
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small-cell lung cancer.15 A retrospective study found that neutrophil count was of 
prognostic value in patients with lung cancer.16 
The aim of this study was to examine and confirm the impact of pretreatment 
peripheral blood neutrophil, monocyte and lymphocyte counts on overall and 
progression-free survival in a well-defined population of patients with advanced 
NSCLC being treated with regimens using newer chemotherapeutic agents in a 
randomized controlled clinical trial. 
 
2. Patients and methods 
2.1 Study population 
A total of 401 chemo-naïve NSCLC patients with stage IIIB with pleural effusion 
or stage IV without brain metastasis, who had Eastern Cooperative Oncology 
Group (ECOG) PS of 0 or 1, were enrolled from 45 institutions in Japan 
between March 2001 and April 2005 into Japan Multinational Trial Organisation 
LC00-0317 (registered with ClinicalTrials.gov identifier NCT00079287). Patients 
underwent one of two treatment regimens: intravenous vinorelbine (25 mg/m2) 
plus gemcitabine (1000 mg/m2) on days 1 and 8 every 21 d for three cycles, 
followed by intravenous docetaxel (60 mg/m2) on day 1 every 21 d for three 
cycles [VGD arm, n=196] versus intravenous paclitaxel (225 mg/m2) and 
carboplatin (area under the curve=6) for 3 h on day1, every 21 d for six cycles 
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[PC arm, n=197]). As there were no significant differences between treatment 
groups in terms of either overall (hazard ratio: 0.996, P=0.974) or 
progression-free survival (hazard ratio: 0.966, P=0.742), the combined data 
from the two arms were analysed in this study. Of 393 eligible patients, 
information regarding pretreatment neutrophils in peripheral blood was not 
available for five patients. Thus, data from 388 patients were included in the 
present study. 
 
2.2 Statistical analysis 
Overall survival was defined as the time from randomisation until death from 
any cause, and progression-free survival was defined as the time from 
randomisation until objective tumour progression or death. Survival curves were 
estimated with the Kaplan-Meier method. Associations between the factors and 
the prognosis were examined with the log-rank test in univariate analyses. The 
prognostic impact of pretreatment peripheral blood neutrophil, lymphocyte and 
monocyte counts, and neutrophil-lymphocyte ratio were examined using the 
proportional hazards regression model to estimate hazard ratios after 
adjustment for covariates without variable selection. Optimal cut-off points for 
continuous variables were selected using the minimum P-value approach with 
correction of the P-value.18 The corrected hazard ratio and its 95% confidence 
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interval (CI) were estimated using a shrinkage procedure with bootstrap 
resampling.19 All statistical analyses were done using SAS version 9.1 (SAS 
Institute, Cary, NC). 
 
3. Results 
3.1 Patient characteristics 
Of 388 patients, 276 patients had died, and the median follow-up time for 112 
surviving patients was 567 d (range: 70-1711 d). The characteristics of the 388 
patients (276 men [71%], 112 women [29%], median age 65 years [range, 33-81 
years], included in the present study are shown in Table 1. Median pretreatment 
counts of neutrophils, lymphocytes and monocytes were 4304/mm3, 1386/mm3, 
and 404.2/mm3, respectively. Spearman’s rank correlations were 0.351 for 
neutrophils and monocytes, −0.034 for neutrophils and lymphocytes and 0.352 
for monocytes and lymphocytes. 
 
3.2 Relationship between pretreatment neutrophil, lymphocyte and 
monocytes counts and survival 
In univariate analyses, pretreatment elevated counts of neutrophils were 
statistically significantly associated with short overall (Fig. 1A, P<0.0001) and 
progression-free survival (Fig. 1B, P=0.0001). Although lymphocyte count did 
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not correlate with survival, there were significant relationships between 
high-neutrophil-lymphocyte ratio and short overall (P<0.0001) and 
progression-free survival (P=0.005). The elevated monocyte count was also 
significantly associated with short overall survival (P=0.004), and moderately 
related to short progression-free survival (P=0.052). We selected sex, smoking 
history, stage, ECOG PS, weight loss, plasma LDH and presence of bone, liver 
or skin metastases as the known pretreatment prognostic factors.2,14 Adjusted 
hazard ratios for the relationship between pretreatment neutrophil, lymphocyte 
and monocyte counts and neutrophil-lymphocyte ratio and overall and 
progression-free survival after adjustment for the known prognostic factors are 
shown in Table 2. There was a statistically significant association between 
elevated neutrophil count and short overall (P=0.0008) and progression-free 
survival (P=0.024), and between high-neutrophil-lymphocyte ratio and short 
overall (P=0.011) and progression-free survival (P=0.040), whereas no 
association was found between lymphocyte or monocyte count and prognosis. 
The relationship between neutrophil count and both overall and 
progression-free survival was linear, whereas the relationship between 
neutrophil-lymphocyte ratio and overall survival was to some degree non-linear. 
 
3.3 Optimal cut-off value for pretreatment neutrophil count 
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In selecting optimal cut-off values for the effect of neutrophil count on overall 
survival, the range between the 5th  percentile (2205/mm3) and the 95th 
percentile (9657/mm3) for distribution of neutrophils was selected, and the 
possible cut-off points at intervals of 500/mm3 from 2500/mm3 to 9500/mm3 
were considered (giving 15 candidate cut-off points). Using the minimum 
P-value approach, the selected cut-off value for neutrophil count was 4500/mm3 
(corrected P=0.0009) and the corrected shrunk hazard ratio was 1.67 (95%CI, 
1.09-2.54, from 100 bootstrap samples; Table 3). The selected optimal cut-off 
value did not change even if we used the stratified proportional hazards model, 
stratified by the combination of all covariates. The median survival time was 
19.3 months (95%CI, 16.5-21.4) for the low-neutrophil group (<4500/mm3, 
n=204) and 10.2 months (95%CI, 8.0-12.3) for the high-neutrophil group 
(>4500/mm3, n=184) (Fig. 2). The results of prognostic factor analysis for overall 
survival are shown in Table 4. In terms of the relative order of significance, 
neutrophil count was one of the most important prognostic factors along with 
ECOG PS (p<0.0001), LDH (p=0.001) and smoking history (p=0.002). The 
adjusted hazard ratios for the relationship between neutrophil count 
(<4500/mm3 versus >4500/mm3) and survival according to the treatment groups 
were 1.62 (95%CI, 1.14-2.30) in the PC arm (n=195) and 1.74 (95%CI, 
1.22-2.48) in the VGD arm (n=193). There was no interaction between the 
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neutrophil count and the treatment arms (P for interaction = 0.437). 
 
3.4 Relationship between pretreatment neutrophil count and intensity 
of chemotherapy 
In order to evaluate the effect of neutrophil count on administration of 
chemotherapy and toxicity, we analysed the dose intensity of chemotherapeutic 
agents and the incidence of toxicity in each arm. In the VGD arm, there was no 
significant difference in the relative dose intensity of vinorelbine or gemcitabine 
between the low-neutrophil group (<4500/mm3) and the high-neutrophil group 
(>4500/mm3). However the relative dose intensity of docetaxel was significantly 
lower in the high-neutrophils group (median, 33%) than in the low-neutrophils 
group (median, 87%) (P=0.040, Wilcoxon test). 
The toxicity due to treatment was also analysed. In the VGD arm, the 
incidence of grade 3 or 4 non-hematological toxicity within the first three cycles 
of treatment was significantly higher in the high-neutrophil group than in the 
low-neutrophil group (26.5% versus 8.5%; P=0.002, Fisher’s exact test). 
Significantly fewer cycles were administered in the high-neutrophil group than in 
the low-neutrophil group (mean, 2.9 cycles versus 4.7 cycles; P<0.0001, 
Wilcoxon test). None of the patients in the high-neutrophil group who 
experienced grade 3 or 4 non-hematological toxicity within the first three cycles 
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completed the planned six cycles. The proportion of patients requiring 
reductions in the doses of vinorelbine or gemcitabine within the first two cycles 
of treatment was significantly higher in the low-neutrophil group (45.2%) than in 
the high-neutrophil group (26.4%) (P=0.007, Fisher’s exact test). No such 
differences in dose intensity or toxicity were seen in the PC arm. 
 
4. Discussion 
In multivariate analysis after adjustment for known prognostic factors, we found 
linear associations between pretreatment elevated neutrophil count and short 
overall and progression-free survival. As there was no such association for the 
lymphocyte count, the relationship between neutrophil-lymphocyte ratio and 
overall survival was also found, however it was to some degree weak and 
non-linear. As a consequence, we consider that absolute neutrophil count may 
better serve as a prognostic factor. An optimal cut-off value for the relationship 
between neutrophil count and overall survival was identified as 4500/mm3 
(corrected hazard ratio, 1.67; 95%CI, 1.09-2.54). In the VGD arm, the 
low-neutrophil group (<4500/mm3) tended to have a lower incidence of severe 
non-hematological toxicity and tolerated longer administration of the 
chemotherapeutic agents compared with the high-neutrophil group. However, 
no such association was found in the PC arm, and pretreatment neutrophil 
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count was equally predictive of prognosis in both treatment arms when 
analysed separately. We therefore do not consider it likely that the pretreatment 
neutrophil count serves as an indicator of intolerance to chemotherapy, rather 
than as an indicator of poor prognosis. 
A number of studies in the last two decades have suggested an association 
between the neutrophil count or neutrophil-lymphocyte ratio and the prognosis 
of cancer patients,7-16 although no acceptable explanations for the mechanisms 
underlying these observed associations have been proposed. Moreover, 
although neutrophilia often accompanies the diagnosis of cancer, the causes of 
neutrophilia in cancer patients are not fully understood, and are likely to be the 
result of a combination of factors. One obvious cause of neutrophilia is 
paraneoplastic production of myeloid growth factors by cancer cells themselves. 
Granulocyte-colony stimulating factor (G-CSF) is a growth factor that acts 
selectively on bone marrow granulocytic lineage cells, and is considered to play 
a central role in granulopoiesis. Administration of G-CSF was reported to 
increase bone marrow neutrophil precursors and shorten bone marrow transit 
time in mice and humans,20-22 resulting in marked increases in the production of 
neutrophils. Granulocyte-macrophage colony stimulating factor (GM-CSF) and 
macrophage-colony stimulating factor are other examples of hematopoietic 
growth factors that cause neutrophilia by in vivo administration.23,24 A variety of 
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non-hematopoietic malignant tumours including mesothelioma,25 squamous cell 
carcinoma of the oropharynx,26 melanoma,27 glioblastoma,28 and carcinoma of 
the lung29 have been reported to secrete G-CSF or GM-CSF and cause 
significant leucocytosis. Although there have been several reports of the 
existence of autocrine growth loops for G-CSF and GM-CSF in 
non-hematopoietic tumour cells, implying G-CSF- and GM-CSF-producing 
tumours are more aggressive,30,31 the relationship between paraneoplastic 
production of myeloid growth factors and prognosis remains unclear. 
Furthermore, considering the linear relationship we observed between 
pretreatment neutrophil count and survival in this study, ectopic production of 
myeloid growth factors, which often causes marked neutrophilia, does not seem 
to be the sole reason for the observed association between neutrophil count 
and prognosis. 
Other possible factors that cause neutrophilia are coexistent infection and 
cancer-related inflammation. In this study, patients with active infection were 
excluded based on the eligibility criteria of the trial, and there is no clear reason 
to assume the existence of latent infection as the cause of neutrophilia and poor 
prognosis. 
The association between cancer and inflammation was initially pointed out 
during the 19th century. However, recent advances in understanding of tumour 
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biology have stimulated renewed interests in searching for links between cancer 
and inflammation.3-6 Today, it is widely accepted that chronic inflammation 
contributes to the initiation and progression of cancer. Furthermore, it is now 
known that inflammatory processes almost always accompany cancer, and 
persistence of chronic inflammation-like processes within cancer tissue causes 
suppression of anti-tumour immunity by several mechanisms such as activation 
of type 2 T-helper responses, recruitment of regulatory T cells and activation of 
the chemokine system, and result in promotion of cancer growth and metastasis. 
Thus, inflammation may result in the aggressive growth of a tumour. The 
cytokines interleukin (IL)-6 and tumour necrosis factor-alpha (TNFα), which are 
implicated in the pathogenesis of cancer-related inflammation as well as of 
acute inflammatory processes, are also known to induce neutrophilia.32-34 It is 
possible that the neutrophil count at diagnosis indicates the severity or nature of 
inflammation occurring within the tumour, and thus reflects prognosis. In a 
recent report, a proportion of patients with metastatic cancer were shown to 
have IL-6-mediated elevation in serum cortisol levels. This may partly explain 
the neutrophilia of cancer patients, although its contribution to outcome is not 
yet known.35  
We did not measure inflammatory markers such as C-reactive protein or 
hemogram of total white cell count in this study. However, we are investigating 
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correlations between several cytokines and prognosis in a correlative study of 
another clinical trial (ClinicalTrials.gov identifier NCT00616031). 
Besides inflammation in cancer tissue, host factors may influence the 
prognosis of cancer patients. It is now known that lifetime exposure to infectious 
diseases and other sources of inflammation is not only related to the 
pathogenesis of cancer, but also plays an important role in aging and influences 
longevity.36,37 Aging is a complex process, and numerous genes are known to 
have associations with longevity.38 Polymorphisms of the genes that encode 
proteins involved in inflammatory processes (e.g., IL-1, IL-6, IL-10 and TNFα) 
are suspected to affect aging and longevity. Given the close relationship 
between cancer and inflammation, it is natural to speculate that genetic 
polymorphisms in inflammation-related genes may also influence host 
responses to cancer and prognosis; peripheral neutrophil count may be an 
indicator of this association. 
Another possibility is that neutrophil directly down-regulates host cellular 
immunity against cancer, thereby affecting the prognosis. In vitro studies 
showed that neutrophils suppress the cytolytic activity of lymphocytes and 
natural killer cells when co-cultured with neutrophils and lymphocytes from 
normal healthy donors; the degree of suppression was proportional to the 
number of neutrophils added.39-41 The clinical relevance of these effects seen in 
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in vitro studies is currently unknown. The biological basis for the multi-factorial 
and complex association is also unknown, and merits further research. 
 
5. Conclusion 
Using the dataset from a randomised controlled trial, we have confirmed that 
pretreatment peripheral blood neutrophil count is an independent prognostic 
factor in patients with advanced NSCLC receiving modern chemotherapy. The 
results need to be investigated for generalisability in other populations. Since 
neutrophil count is easily measured at low cost, it may be a useful predictor of 
prognosis in clinical practice. Considering the strength of the association 
reported here, neutrophil count should be taken into account as a stratification 
factor in future randomised clinical trials of patients with advanced NSCLC. 
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Table 1. Baseline patient characteristics (n=388) 
 
Characteristics No. % 
Age, years, Median (Range) 65 (33-81) 
Sex 
  Male 











































ECOG Performance status 
  0 







Weight loss (from 6months before enrolment) 
  < 5% 








  Normal (< ULN) 








  No 








  No 








  No 







Neutrophils, /mm3, Median (range) 4304 (205-17100) 
Lymphocytes, /mm3, Median (range) 1386 (243-4200) 
Monocytes, /mm3, Median (range)a 404.2 (0-1620) 
Red blood cells, x104/mm3, Median (range) 420 (286-579) 
Platelets, x104/mm3, Median (range)b 26 (11-380) 
ULN: upper limit of normal 
a: One missing value 
b: Two missing values 
  
Table 2. Multivariate Cox regression analysis for neutrophil, lymphocyte and monocyte counts 
 
Factors Overall survival Progression-free survival 
Hazard 
Ratioa 
95%CI p pb Hazard 
Ratioa 
95%CI p pb 
Neutrophil count (/mm3) 
  Quartile 1 (< 3278) 
  Quartile 2 (< 4304) 
  Quartile 3 (< 5873) 
  Quartile 4 (> 5873) 
 
Lymphocyte count (/mm3) 
  Quartile 1 (< 1082.3) 
  Quartile 2 (< 1386.1) 
  Quartile 3 (< 1821.8) 




  Quartile 1 (< 2.093) 
  Quartile 2 (< 2.914) 
  Quartile 3 (< 4.744) 
Quartile 4 (> 4.744) 
 
Monocyte count (/mm3) 
  Quartile 1 (< 289.9) 
  Quartile 2 (< 402.3) 
  Quartile 3 (< 550.4) 



























































































































































































CI: confidence interval 
a: Adjustment for sex, smoking, stage, ECOG PS, weight loss, LDH, bone metastases, liver 
metastases and skin metastases 
b: P values for global association
  
Table 3. Cutpoint analysis for neutrophil count and overall survival 
 
Neutrophil count 


















































a: (hazard of death in patients on or above the cut-off point) divided by (hazard of death in 
patients below the cut-off point), after adjustment for sex, smoking, stage, ECOG PS, weight 
loss, LDH, bone metastases, liver metastases and skin metastases 
b: Corrected hazard ratio: 1.67 (95%CI, 1.09-2.54) 
c: Corrected P=0.0009 
  
Table 4. Prognostic factor analysis for overall survival using proportional hazards regression 
model without variable selection 
 
Factors Hazard Ratio 95%CI P-value 
Performance status 
  0 
  1 
Neutrophil count 
  < 4500/mm3 
  > 4500/mm3 
LDH 
  Normal 
  High 
Smoking history 
  Non/Former smokers 
  Current smokers 
Liver metastases 
  No 
  Yes 
Sex 
  Male 
  Female 
Weight loss 
  < 5% 
  > 5% 
Skin metastases 
  No 
  Yes 
Bone metastases 
  No 
  Yes 
Stage 
  IIIB 































































































Figure 1. Kaplan-Meier estimates according to quartiles for the effect of 
pretreatment neutrophil count on (A) overall survival (B) progression-free 
survival. 
 
Figure 2. Kaplan-Meier estimates according to optimal cut-off point (4500/mm3) 
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